点击分子即可查看您感兴趣的产品详情哦 ~
1.药物质控分析方法
Immobilized Human CD3E&CD3D Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. CDD-H5255) at 1 μg/mL (100 μL/well) can bind Bispecific BCMA×CD3 T cell-engaging Antibody with a linear range of 0.8-6 ng/mL.
Protocol
2.PK分析方法
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL, add increasing concentrations of Bispecific T cell Engager (CD3 X BCMA) in 10% human serum and then add Biotinylated Human CD3E&CD3D Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDD-H82W6) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 15 ng/mL.
Protocol
灵活的分析方法可供您的定制检测需求选择
免费提供实验所需全部CD3靶点蛋白,更有方案打包价格优惠供您选择!
ACROBiosystems开发的高度均一的高活性CD3系列产品,经非还原电泳和MALS技术严格确认为1:1异源二聚体。
Human CD3E&CD3D Heterodimer Protein (Cat. No. CDD-H52Wa) on SDS-PAGE under reducing (R) and non-reducing(NR)condition and the purity of the protein is greater than 95%. The purity of the protein is more than 85% and around 80-90 kDa verified by SEC-MALS.
Protocol
CD3系列产品为严格确认的1:1异源二聚体,更加接近T细胞表面天然蛋白的结构,因此在各种应用场景中表现出高活性。产品高度均一,并采用多种分析技术进行全面严格质控,批间差最小。
Immobilized Biotinylated Human CD3E&CD3D Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDD-H82W6) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3) (Cat. No. CDE-M120a) with a linear range of 0.2-6 ng/mL (QC tested), and batch differences EC50<0.0001 μg/mL.
产品适合药物开发的不同阶段的多种应用场景,比如抗体免疫滴度检测,Biopanning抗体筛选,亲和力测定和临床血药浓度分析等。
Immobilized Human BCMA Protein, His Tag (HPLC-verified) (Cat. No. BCA-H522y) at 2 μg/mL, add increasing concentrations of Bispecific T cell Engager (CD3×BCMA) and then add Biotinylated Human CD3E&CD3D Heterodimer Protein, Fc,His Tag&Fc,Flag Tag, primary amine labeling (Cat. No. CDD-H82W0) at 1 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.39 ng/mL (Intact assay, Routinely tested).
Protocol
Bispecific T-cell Engager (CD3×DLL3) captured on Protein A Chip can bind Human CD3 epsilon, His Tag (Cat. No. CDE-H5223) with an affinity constant of 0.843 nM as determined in a SPR assay (Biacore 8K).
Protocol
Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) at 2 μg/mL, add increasing concentrations of Glofitamab and then add HRP-Human CD3E&CD3D Heterodimer Protein, His Tag&Tag Free (Cat. No. CDD-HR2W3) at 1 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Cat. No. STN-NH913) with sensitivity of 40.30 ng/mL (Routinely tested).
Protocol
Immobilized Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) at 2 μg/mL, add increasing concentrations of Glofitamab and then add Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 41.71 ng/mL (Routinely tested).
Protocol
Immobilized Human BCMA, Mouse IgG2a Fc Tag (Cat. No. BCA-H5253) at 1 μg/mL, add increasing concentrations of Teclistamab and then add Biotinylated Human CD3E&CD3G Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDG-H82W3) at 1 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Cat. No. STN-NH913) with sensitivity of 20.12 ng/mL (Routinely tested).
Protocol
Immobilized Human DLL3, His Tag (Cat. No. DL3-H52H4) at 0.2 μg/mL, add increasing concentrations of Tarlatamab and then add Biotinylated Human CD3 epsilon, His,Avitag (Cat. No. CDE-H82E1) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Cat. No. STN-NH913) with sensitivity of 8.21 ng/mL (Routinely tested).
Protocol
Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL, add increasing concentrations of Bispecific T cell Engager (CD3×BCMA) in 10% human serum and then add Biotinylated Human CD3E&CD3D Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDD-H82W6) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 15 ng/mL.
Protocol